Introduction oestrogen receptor content in fibroid, myometrium and endometrium and the phase of the cycle (Soules and Uterine fibroids are the most common benign tumours in women during their reproductive years and one of the most McCarty, 1982) . In this study we report the results of the use of danazol frequent causes of major surgery in women of reproductive age (Buttram and Reiter, 1981; Berkeley et al., 1983) . Most after suspension of analogue therapy. Danazol is a synthetic steroid used for many years in hormonal treatment of symptoms experienced by women with uterine myomas are due either to large pelvic masses or uterine bleeding. Until endometriosis (Dmowski and Cohen, 1975) . The original clinical application of this steriod was based on its now treatment of symptomatic patients has been primarily surgical, although there have been attempts at medical antigonadotrophic properties, demonstrated in animals and patients in whom the induction of amenorrhoea, inhibition treatment with progesterone and gestrinone (Mixon and Hammond, 1961; Sadan et al., 1987; Countinho and of gonadal steroids and block of pituitary gonadotrophins was expected to be beneficial (Franchimont and Cramilion, Goncalves, 1989) . Clinicians have long recognized that fibroids may depend on oestrogen for their growth. These 1977; Dmowski et al., 1983) . Danazol is in fact an isoxazole derivative of 17 α-ethinyl testosterone (ethisterone), another tumours are rarely found before puberty, they increase in size during pregnancy and after oestrogen administration synthetic steroid. It exerts multiple effects at various sites of the female reproductive system, as direct and indirect and regress after menopause and ovariectomy (Buttram and Reiter, 1981) . Histological evidence of endometrial consequences of its binding affinity for intracellular steroid receptors, its interaction with two circulating steroid binding hyperplasia near submucous fibroids suggests that local one and OC levels were present in each assay. Assay sensitivities proteins, and its capacity to inhibit certain enzymes involved were 0.3 mIU/ml for LH, 0.25 mIU/ml for FSH; 5 pg/ml for oestradiol, in gonadal and adrenal steroidogenesis (Barbieri et al., 1979) . 50 pg for progesterone and 0.5 pg/ml for OC. Inter-and intra-assay coefficients of variation were 3.1 and 2.5% for FSH, 7.0 and 5.0% for LH, 3.5 and 3.2% for oestradiol, 8.5 and 10.8% for progesterone
Material and methods
and 4.5 and 6.8% for OC respectively.
Patients
Bone mineral density Twenty-one women, aged 31-45 years, were enrolled in the study. Of these, 17 had symptomatic uterine leiomyomata found to be Bone mineral density (BMD) was measured by dual X-ray absorptiincreasing in size. Four women were asymptomatic and were found ometry (Ostescan Nim, Verona, Italy) in the distal radius of the nonto have leiomyomata on routine pelvic examination. The main dominant forearm before therapy and every 3 months. symptoms included pelvic pressure and/or pain, menorrhagia, urinary Statistical analysis frequency and dysmenorrhoea. None of the women had used hormonal medication in the 3 months prior to enrolment or had even taken Plasma hormone levels (as mean Ϯ SD) were expressed in mIU/ml GnRHa. None had any serious concomitant medical condition such as (LH; FSH), pg/ml (oestradiol; progesterone) and ng/ml (OC) (Table hormonal dysfunction. Before beginning therapy all women underwent I). Comparisons between treatments were performed at each time gynaecological examination and cervical smear. Blood pressure was point (weeks 12 and 24 after start of GnRHa treatment and weeks measured and routine blood tests, including lipid profile and clotting 12 and 24 of follow-up) by analysis of variance (ANOVA). The factors, were performed and found to be within normal limits; only comparison within treatment groups was made by Student's t-test for red cell concentration and haemoglobin were below normal in paired and unpaired data. some cases.
Results

Treatment protocol
Oestradiol plasma levels in both treatment groups showed showed a significant reduction (P Ͻ 0.01) during treatment Milan, Italy) to determine uterine myoma volume. These instrumental with oestradiol plasma levels Ͻ20 pg/ml in both groups in evaluations were performed in three dimensions either vaginally and/ weeks 12 and 24 of treatment (Table I ). The patients were or abdominally. Blood samples were taken to assay oestradiol, amenorrhoeic after the second injection.
progesterone, luteinizing hormone (LH), follicle stimulating hormone A significant reduction (P Ͻ 0.001) in uterine myoma (FSH) and bone mineral content (BMC) was also determined every volume was observed after 12 weeks of GnRHa therapy. determined by serial pelvic ultrasound examination. We did 28 days for 6 months according to a randomized protocol. The not observe significant differences in uterine volume reduction difference between the two GnRHa was insignificant for our study. Some years ago we showed a similar ovarian suppression after 12-between groups treated with the two GnRHa. All patients 15 days from injection in patients treated with goserelin or triptorelin experienced partial or complete relief of symptoms while using (De Leo et al., 1992) . GnRHa therapy was initiated in mid to late GnRHa. At the end of GnRHa therapy we observed a gradual luteal phase. Patients were seen at 2 month intervals during the increase in uterine volume over a 6-month period in groups A treatment period for 1 year. After GnRHa therapy all patients were and B. This increase was much greater in the group without treated with 100 mg danazol for a further 6 months (group B). danazol treatment (group A). At 6 months follow-up the The control group was a previously conducted series consisting of rebound in uterine volume in group B was 31.2% less than in 12 age-matched (34-41 years) women with uterine leiomyomata group A (P Ͻ 0.001).
treated for 6 months with GnRHa (triptorelin) and examined 6 months Menstrual cyclicity returned after 65 Ϯ 3 days from last after the end of therapy (group A). This control group was composed GnRHa injection in all women, except for five patients in group of women treated previously, between November 1993 and June 1994 B who remained amenorrhoeic. Hormone assays confirmed that before the begining the actual protocol. The women had menorrhagia, metrorrhagia, pelvic pain and anaemia. Age distribution in the two ovarian function was restored in the women whose menstrual groups was comparable. In group A, mean age was 38.26 years and periods returned. Basal oestradiol concentrations observed in in group B 37.64 years. follicular phase in the group treated with danazol (group B) were lower than in controls (group A) (Table I) The other Hormone assays hormones reported in Table I were similar in the two groups.
Venous blood samples were taken for assay of LH, FSH, oestradiol, BMD declined during GnRHa treatment and was significprogesterone and osteocalcin (OC) before the start of therapy and at antly higher 6 months after the end of therapy in all patients, 8-weekly intervals during the 1 year of treatment.
including the five women remaining amenorrhoeic (Figure 2) .
The blood was centrifuged and the serum stored at - 20°C until In the patients treated with danazol, the increment in BMD analysis. Plasma FSH, LH, oestradiol, progesterone and OC levels was more rapid than in the group without danazol therapy.
were measured by double antibody radioimmunoassay with commerOsteocalcin levels (Figure 3) showed a significant increase in cial kits. Samples were assayed in duplicate, at two different dilutions.
both groups during the 6 months of GnRHa therapy. After the All samples from a given subject were assayed together. Quality control pools at low, normal and high LH, FSH, oestradiol, progesterend of therapy, osteocalcin levels returned to the normal range. Table I . Hormone concentrations observed before and every 3 months during gonadotrophin-releasing hormone analogue (GnRHa) therapy in group A and B (follicular phase) and after discontinuing GnRHa in group A (control) and group B (treated with 100 mg/day of danazol). The blood samples were taken in follicular phase
Danazol reduces rebound of myomas after GnRHa therapy
Basal
GnRHa therapy After GnRHa therapy 0 3 6 9 1 2
LH (mIU/ml) 8.4 Ϯ 2 9.3 Ϯ 2.5 2.1 Ϯ 0.3 1.5 Ϯ 0.6 1.8 Ϯ 0.5 1.3 Ϯ 0.5 6.7 Ϯ 2.2 5.3 Ϯ 1.6 9.5 Ϯ 3 6.1 Ϯ 2.4 FSH (mIU/ml) 7.7 Ϯ 1.1 6.5 Ϯ 1.6 2.5 Ϯ 0.3 2.1 Ϯ 0.3 2.0 Ϯ 0.5 2.0 Ϯ 0.6 5.9 Ϯ 2.2 6.1 Ϯ 1.9 8.5 Ϯ 2.7 6.4 Ϯ 1.5 Oestradiol (pg/
pg/ml) Prolactin (ng/ml) 9.5 Ϯ 3.1 11.2 Ϯ 2 7.0 Ϯ 1.5 6.3 Ϯ 2.4 5.6 Ϯ 1.2 7.1 Ϯ 1.8 8.1 Ϯ 2.9 8.0 Ϯ 2 11.0 Ϯ 4 9.0 Ϯ 3.2 LH ϭ luteinizing hormone. FSH ϭ follicle stimulating hormone. A ϭ analogue. B ϭ analogue ϩ danazol.
milieu is required for leiomyoma growth and suggest that inducing a state of reduced oestrogen secretion may be useful in the medical management of uterine myomas. The finding that induction of menopause by GnRHa led to a reduction in fibroid size opened the way to the use of these compounds in the treatment of myomas. The basic understanding was that oestrogen induced fibroid proliferation and, if suppressed, this would stop. The difficulty is that when GnRHa therapy is stopped, an increase in fibroid volume is observed (Letterie et al., 1989) . In the present study, an increase in uterine volume was observed in association with increases in serum concentrations of oestradiol and progesterone as menstrual cyclicity resumed. stimulate fibroid growth (Tamaya et al., 1985; Rein et al., 1995) . Both oestrogen and progesterone receptors have been Haemoglobin concentrations and haematocrit increased sigdetected in myometrium and myomas (Buchi and Keller, nificantly during treatment with the two analogues. Haemo-1980) . Myometrial and myoma tissue cultures supplemented globin increased from 11.1 Ϯ 0.6 mg/ml before therapy to with progesterone grew significantly. The observation that 12.7 Ϯ 0.4 mg/ml after 6 months. Haematocrit (%) increased uterine myomas do not regress in patients treated with GnRHa from 35.3 Ϯ 1.4 to 39.6 Ϯ 0.5 after 6 months. Serum plus medroxyprogesterone acetate shows that progesterone cholesterol increased slightly from 185 Ϯ 6 to 197 Ϯ 18 mg/ inhibits the ability of GnRHa to shrink uterine myomas (Carr dl in the danazol group but there was no change in serum et al., 1993) . Myoma mitotic activity is higher in early luteal triglycerides.
phase than in follicular phase (Buchi and Keller, 1983) . Murphy During GnRHa therapy, vasomotor symptoms were reported et al. (1993) showed that an antiprogesterone, RU486, induced by 75% of patients, vaginal dryness by 30% and transient a reduction in myoma size and suggested the use of antiprogesheadaches by 48%. These symptoms disappeared with the terone in the treatment of myomas. These data support an return of menstrual cyclicity when oestradiol levels returned important role for progesterone in the development and growth to the normal range for fertile women. The five amenorrhoeic of uterine myomas. women on danazol also reported the disappearance of menoThe major problems with long term GnRHa treatment are pausal symptoms. menopausal symptoms and bone loss. Another difficulty is the fact that uterine volume usually returns to pretreatment values Discussion within 3-6 months of discontinuing GnRHa therapy. Danazol binds to the progesterone receptor with an affinity The present study shows the efficacy of GnRHa in the treatment that is 3% that of progesterone (Franchimont and Cramillon, of symptomatic and asymptomatic myomas and demonstrates 1977). Moreover, danazol is able to displace progesterone that rebound of myoma volume after discontinuing therapy from human and myometrial cytosol suggesting a direct can be reduced by administering low doses of danazol.
antiprogestational activity in the human (Chamnes et al., 1980) . The prevalence of myomas among patients of reproductive For these reasons, we decided to use danazol after discontinuing age and their tendency to regress after menopause suggest that GnRHa therapy in the treatment of uterine myomas. this disorder is hormone dependent (Vollenhoven et al., 1990) .
Clinical and laboratory data demonstrate that an oestrogenic
The danazol dose given to the patients was well tolerated.
